Ryan E J, Daly L M, Mills K H
Institute of Immunology, National University of Ireland, Maynooth, Co., Kildare, Ireland.
Trends Biotechnol. 2001 Aug;19(8):293-304. doi: 10.1016/s0167-7799(01)01670-5.
Current paediatric immunization programmes include too many injections in the first months of life. Oral or nasal vaccine delivery eliminates the requirement for needles and can induce immunity at the site of infection. However, protein antigens are poorly immunogenic when so delivered and can induce tolerance. Novel ways to enhance immune responses to protein or polysaccharide antigens have opened up new possibilities for the design of effective mucosal vaccines. Here, we discuss the immunological principles underlying mucosal vaccine development and review the application of immunomodulatory molecules and delivery systems to the selective enhancement of protective immune responses at mucosal surfaces.
目前的儿科免疫计划在生命的最初几个月包含过多的注射。口服或鼻内疫苗接种消除了对针头的需求,并且可以在感染部位诱导免疫。然而,以这种方式递送时,蛋白质抗原的免疫原性较差,并且可能诱导耐受性。增强对蛋白质或多糖抗原免疫反应的新方法为有效黏膜疫苗的设计开辟了新的可能性。在此,我们讨论黏膜疫苗开发的免疫学原理,并综述免疫调节分子和递送系统在选择性增强黏膜表面保护性免疫反应中的应用。